Form 4: QuidelOrtho CFO Joseph M. Busky Awarded Restricted Stock Units
SEC Form 4 Filing
QuidelOrtho's Chief Financial Officer, Joseph M. Busky, was granted 25,276 restricted stock units on January 29, 2025, which will vest over the next three years.
Summary
- Joseph M. Busky, the Chief Financial Officer of QuidelOrtho Corp, was granted 25,276 restricted stock units on January 29, 2025.
- These restricted stock units represent the right to receive one share of QuidelOrtho common stock per unit.
- The vesting schedule for these units is staggered, with 16,850 shares vesting in equal installments on January 29, 2026, and January 29, 2027.
- The remaining 8,426 shares will vest on January 29, 2028.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications or surprises.
Positives
- The grant of restricted stock units aligns the CFO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
The granting of restricted stock units is a common practice in corporate compensation to align executive interests with shareholder value and encourage long-term performance.
Comparison to Industry Standards
- The use of restricted stock units is a standard practice for executive compensation across various industries, including the healthcare and diagnostics sector where QuidelOrtho operates.
- Companies like Abbott Laboratories, Danaher Corporation, and Thermo Fisher Scientific also use similar equity-based compensation plans for their executives.
- The vesting schedule of three years is also typical, designed to retain key personnel and incentivize long-term value creation.
Stakeholder Impact
- Shareholders may view this as a positive sign of aligning management interests with long-term company performance.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of the restricted stock unit grant. |
| 01/29/2026 | First vesting date for 8,425 shares. |
| 01/29/2027 | Second vesting date for 8,425 shares. |
| 01/29/2028 | Final vesting date for 8,426 shares. |
| 01/31/2025 | Date of the form filing. |
Keywords
Restricted Stock Units, Stock Options, Executive Compensation, Form 4, QuidelOrtho, Joseph M. Busky, CFO, Equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.